Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Bayer Czech Republic generated the highest earnings before interest cost, taxes and depreciation (so called EBITDA) in 2017 followed by Pfizer Czech Republic and Novartis Czech Republic.
Bayer Czech Republic made EBITDA of CZK 158 mil, down 32.3% compared to the previous year. Historically, the firm’s EBITDA reached an all time high of CZK 233 mil in 2016 and an all time low of CZK -10.0 mil in 2007. The average profit in the last five years amounted to CZK 167 mil.
The company generated an average EBITDA margin of 4.11% for its shareholders in the last five years with a maximum of 5.38% and a minimum of 3.53%.
Comparing Bayer Czech Republic with its closest peers, Pfizer Czech Republic generated EBITDA of CZK 156 mil with a EBITDA margin of 4.36% in 2017, Novartis Czech Republic grossed CZK 138 mil (EBITDA margin of 2.18%) and GlaxoSmithKline Czech Republic announced a profit of CZK 97.4 mil translating into a margin of 3.36%.
|Roche Czech Republic||CZK mil||208||204||328||265||209||...|
|Merck Czech Republic||CZK mil||67.1||83.8||49.2||53.6||95.9|
|Amgen Czech Republic||CZK mil||58.3||37.3||41.1||54.4||46.3|
|Pfizer Czech Republic||CZK mil||316||66.4||173||172||110|
|Bayer Czech Republic||CZK mil||168||112||135||143||168|
|GlaxoSmithKline Czech Republic||CZK mil||310||234||189||139||139|
|Sanofi-Aventis Czech Republic||CZK mil||90.8||80.9||98.9||17.0||94.6|
|Novartis Czech Republic||CZK mil||61.6||69.8||71.6||113||131|
|Servier Czech Republic||CZK mil||...||...||19.2||20.1||20.8||23.8|